Since the 1970s, Japanese neurologists have described patients with autosomal recessive forms of familial Parkinson disease (PD), 6 which have been termed "autosomal recessive juvenile parkinsonism" and "early-onset parkinsonism with diurnal fluctuation," both of which have become known as "PARK2" (1 ) . We attempted to identify the gene responsible for autosomal recessive familial PD. In 1997, we identified, along with our collaborators, an autosomal recessive familial PD gene between D6S437 and D6S264 (2 ) , and in 1998 we found that mutations in that gene were linked to autosomal recessive familial PD. We designated the gene, formerly known as parkin, as PARK2 A year later, we demonstrated that parkin was produced in the substantia nigra and localized in Lewy bodies (4 ) . The function of parkin remained unknown, however. In 2000, in collaboration with Keiji Tanaka, Toshiaki Suzuki, Tomoaki Chiba, Shin-ichiro Kubo, Kazuhiro Iwai, Shuichi Asakawa, Shinsei Minoshima, and Nobuyoshi Shimizu, we were able to identify parkin as a ubiquitinprotein ligase that facilitates the degradation of proteins that interact with ubiquitin-conjugating enzyme UbcH7. We reported our results in the Nature Genetics article featured here. Ubiquitin is an interesting protein because it is localized in Lewy bodies, which are the pathologic hallmarks of PD. Ubiquitin is a small covalent modifier that forms a polyubiquitin chain on proteins. The polyubiquitin chain, which becomes a degradation signal for proteasome or lysosomal degradation or a signal for other processes, is synthesized by a cascade reaction involving the 3 enzymes ubiquitinactivating enzyme, ubiquitin-conjugating enzyme, and ubiquitin-ligating enzyme, which act as substraterecognition molecules. We showed that (a) parkin has ubiquitin ligase activity with UbcH7, (b) the mutations in parkin that cause PD cause a loss of its ubiquitin ligase activity, and (c) proteasome inhibition leads to an accumulation of unknown parkin substrates in SH-SY5Y cells, indicating that the part of parkin linked to ubiquitination is a recognition signal for proteasomal degradation. Thus, our Nature Genetics article presented the important finding that impairment in the proteindegradation system causes dopaminergic cell death in PD. We speculated that substrates of parkin accumulate in parkin-deficient brains because of insufficient ubiquitination by mutant parkin. The accumulation of substrates may cause neuronal death in PD. We also suggested that unknown substrates of parkin might play important roles in PD pathogenesis.
To date, Ͼ100 parkin mutations have been identified. Various reported substrates of parkin include CDC-rel-1, O-glycosylated a-synuclein, the parkinassociated endothelin-like receptor, the ␣-synucleinbinding protein synphilin-1, actin filaments, the poly(Q)-expanded mutant of ataxin-3, Huntington disease polyglutamine proteins, the amyloidogenic Alzheimer disease Ab1-42 peptide (amyloid ␤ peptide 1-42), and ab-tubulin. In support of these findings, parkin-linked animal models have shown a dysregulation of dopaminergic cells. Additionally, parkin activity is decreased in sporadic PD. Parkin is considered to play an important role in familial PD and other neurodegenerative disorders. Parkin is a broad neuroprotective agent that acts against a wide range of toxic insults, including those that are not part of the ubiquitinproteasome system. Parkin also associates with mitochondrial membranes and interacts with the phosphatase and tensin homolog-induced putative kinase gene to protect mitochondrial function. Clarifying the relationships between parkin, ubiquitination, and mitochondria may provide insights into PD pathogenesis.
